Advancing Dignity, Health, and Optimism in Connection With Long Acting Injectables
ADHOC-LA is an observational study of people living with HIV who either are taking, or have taken, a long-acting injectable therapy to manage their HIV. Data from this study will be used to research the ways in which HIV impacts the lives of these patients.
Conditions:
🦠 HIV
🗓️ Study Start (Actual) 20 May 2021
🗓️ Primary Completion (Estimated) 20 May 2026
✅ Study Completion (Estimated) 20 May 2026
👥 Enrollment (Estimated) 200
🔬 Study Type OBSERVATIONAL
📊 Phase N/A
Locations:
📍 Menlo Park, California, United States

📋 Eligibility Criteria

Description

  • Eligibility Criteria:
  • 1. Have an HIV-1 infection
  • 2. a) Currently take a long-acting injectable therapy for HIV supplied by ViiV as part of a ViiV-sponsored, long-acting injectables therapy trial (LATTE-2, ATLAS-2M, CUSTOMIZE, POLAR, FLAIR, or SOLAR), or
  • b) Currently take a long-acting injectable therapy for HIV prescribed by their provider, not in conjunction with a ViiV-sponsored clinical trial, or
  • c) No longer taking long-acting injectable therapy for HIV, but previously received three or more injections of long-acting injectable therapy, either:
  • * Supplied by ViiV as part of a ViiV-sponsored, long-acting injectables therapy trial (LATTE-2, ATLAS-2M, CUSTOMIZE, POLAR, FLAIR, or SOLAR), or
  • * Prescribed by their provider, unrelated to a ViiV-sponsored clinical trial.
  • 3. Age 18 or above
  • 4. Have no known acute medical problem requiring immediate inpatient treatment
  • 5. Able to read and write in English
  • 6. Able and willing to provide online informed consent and to complete the online profile
  • 7. Not currently enrolled in another clinical trial in which the participant is receiving a long-acting injectable therapy for HIV.
  • Participants who meet the eligibility criteria but are still receiving ViiV-supplied drug may enroll in the registry, but will not begin the online questionnaire until they are rolled off of ViiV-supplied long-acting injectable therapy.
Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 21 December 2021
  • First Submitted that Met QC Criteria 13 January 2022
  • First Posted 26 January 2022

Study Record Updates

  • Last Update Submitted that Met QC Criteria 13 January 2022
  • Last Update Posted 26 January 2022
  • Last Verified January 2022